<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-7026</journal-id>
<journal-title><![CDATA[Psicología, Conocimiento y Sociedad]]></journal-title>
<abbrev-journal-title><![CDATA[Psicol. Conoc. Soc.]]></abbrev-journal-title>
<issn>1688-7026</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Psicología. Universidad de la República]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-70262018000200005</article-id>
<article-id pub-id-type="doi">10.26864/pcs.v8.n2.2</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La metafísica tras la farmacoterapia: tratando la depresión con fármacos convencionales y psicodélicos]]></article-title>
<article-title xml:lang="en"><![CDATA[The metaphysics behind pharmacotherapy: treating depression with conventional and psychedelic drugs]]></article-title>
<article-title xml:lang="pt"><![CDATA[A metafísica tras a farmacoterapia: tratando a depressão com fármacos convencionais e psicodélicos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ballesteros]]></surname>
<given-names><![CDATA[Virginia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Valencia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>8</volume>
<numero>2</numero>
<fpage>5</fpage>
<lpage>24</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-70262018000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-70262018000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-70262018000200005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El propósito de este artículo es comparar las implicaciones metafísicas de la aproximación psicofarmacológica convencional al tratamiento de la depresión, con las implicaciones de la aproximación mediante drogas psicodélicas. Examinaremos la tesis según la cual el conocimiento sobre cómo actúan sobre nosotros los fármacos moldea nuestra auto-imagen y nuestra comprensión de la psicopatología -y defenderemos que este proceso sólo ocurrir en un entorno adecuado-. Suele afirmarse que la naturaleza de la depresión fue inferida a partir del éxito terapéutico de los antidepresivos; no obstante, los psicodélicos fueron tan exitosos como los antidepresivos y, en cambio, no ejercieron la misma influencia en nuestra visión. Los antidepresivos de primera y segunda generación pudieron influenciar nuestra mirada porque se encontraban en un entorno propicio para ello. Cuestiones sociales, políticas, económicas e incluso metafísicas entraron en juego para llegar a ese resultado. Compararemos el despliegue de estos dos paradigmas suscitados por sendos fármacos: uno, donde los fármacos son vistos como fórmulas mágicas cuya meta es restablecer el equilibrio bioquímico; otro, donde los fármacos son vistos como herramientas terapéuticas capaces de inducir una experiencia capaz de cambiar la vida del paciente, en el contexto apropiado. Revisaremos los factores que contribuyeron al establecimiento de un paradigma reduccionista, tales como las aspiraciones científicas de la psiquiatría y la identificación de las explicaciones biologicistas con el terreno de la objetividad. Finalmente, reflexionaremos sobre el nuevo paradigma que se abre con la investigación contemporánea.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: This paper aims to explore and compare the metaphysical entailments of the conventional psychopharmacological approach in the treatment of depression to those of a psychedelic approach. We will examine the thesis by which knowledge of how drugs act upon us shapes our self-image and our understanding of psychopathology--and defend that this process can only take place in a supportive environment. It is commonly claimed that the nature of depression was shaped after the therapeutic success of antidepressants; nevertheless, psychedelic drugs were at least as successful as antidepressants, and they didn&#8217;t end up having the same power to influence our views. It was possible for first and second-generation antidepressants to influence our views because of a supportive environment, where social, political, economic and even metaphysical issues were at play to create that result. We will compare the unfolding of the two paradigms elicited by these two kinds of drugs, one where pills are seen as magic bullets aimed to restore biochemical balance, and another where drugs are seen as therapeutic tools capable of inducing a life-changing experience, provided there is an adequate context. We will review different factors that contributed to the establishment of a reductionist paradigm, such as the aspirations of psychiatry and the assumed objectivity of biologically oriented explanations. Finally, we will reflect on the new paradigm that unfolds with contemporary research.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: Este trabalho tem como objetivo explorar e comparar as implicações metafísicas da abordagem psicofarmacológica convencional no tratamento da depressão com aqueles de uma abordagem psicodélica. Examinaremos a tese segundo a qual o conhecimento de como as drogas agem sobre nós molda nossa auto-imagem e nossa compreensão da psicopatologia, e defenderemos que este processo só pode ocorrer em um quadro favorável. É comumente alegado que a natureza da depressão foi moldada após o sucesso terapêutico dos antidepressivos; no entanto, as drogas psicodélicas eram pelo menos tão bem sucedidas quanto os antidepressivos, e não acabavam tendo o mesmo poder de influenciar nossas opiniões. Era possível que os antidepressivos de primeira e segunda geração influenciassem nossas visões por causa de um quadro favorável, onde questões sociais, políticas, econômicas e até mesmo metafísicas estavam em jogo para chegar a esse resultado. Compararemos o desenvolvimento dos dois paradigmas promovidos por esses dois tipos de drogas, um onde as pílulas são vistas como fórmulas mágicas destinadas a restaurar o equilíbrio bioquímico e outro onde as drogas são vistas como ferramentas terapêuticas capazes de induzir uma experiência transcendental. Revisaremos diversos fatores que contribuíram para o estabelecimento de um paradigma reducionista, como as aspirações da psiquiatria e a suposta objetividade das explicações biologicamente orientadas. Finalmente, refletiremos sobre o novo paradigma que se desenvolve na pesquisa contemporânea.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Monoamine hypothesis]]></kwd>
<kwd lng="en"><![CDATA[Therapeutic tool]]></kwd>
<kwd lng="en"><![CDATA[Experience]]></kwd>
<kwd lng="en"><![CDATA[Context.]]></kwd>
<kwd lng="es"><![CDATA[Hipótesis monoaminérgica]]></kwd>
<kwd lng="es"><![CDATA[Herramienta terapéutica]]></kwd>
<kwd lng="es"><![CDATA[Experiencia]]></kwd>
<kwd lng="es"><![CDATA[Contexto.]]></kwd>
<kwd lng="pt"><![CDATA[Hipótese monoaminérgica]]></kwd>
<kwd lng="pt"><![CDATA[Ferramenta terapêutica]]></kwd>
<kwd lng="pt"><![CDATA[Experiência, Contexto]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baumeister]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Giaroli]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Tracy]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles]]></article-title>
<source><![CDATA[Therapeutic Advances in Psychopharmacology]]></source>
<year>2014</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>156-69</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carhart-Harris]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bolstridge]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rucker]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[C. M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Erritzoe]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaelen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Nutt]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study]]></article-title>
<source><![CDATA[The Lancet Psychiatry]]></source>
<year>2016</year>
<volume>3</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>619-27</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carhart-Harris]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[G. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2017</year>
<volume>42</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2105-13</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cowen]]></surname>
<given-names><![CDATA[P. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Browning]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What has serotonin to do with depression?]]></article-title>
<source><![CDATA[World Psychiatry]]></source>
<year>2015</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>158-60</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eisner]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Set, Setting, and Matrix]]></article-title>
<source><![CDATA[Journal of Psychoactive Drugs]]></source>
<year>1997</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>213-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffiths]]></surname>
<given-names><![CDATA[R. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[M. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Carducci]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Umbricht]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[W. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[B. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Klinedinst]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial]]></article-title>
<source><![CDATA[Journal of Psychopharmacology]]></source>
<year>2016</year>
<volume>30</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1181-97</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grinspoon]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bakalar]]></surname>
<given-names><![CDATA[J. B.]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychedelic drugs reconsidered]]></source>
<year>1979</year>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Lindesmith Center]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harmer]]></surname>
<given-names><![CDATA[C. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cowen]]></surname>
<given-names><![CDATA[P. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8217;It&#8217;s the way that you look at it&#8217;--a cognitive neuropsychological account of SSRI action in depression]]></article-title>
<source><![CDATA[Philosophical Transactions of the Royal Society B: Biological Sciences]]></source>
<year>2013</year>
<volume>368</volume>
<numero>1615</numero>
<issue>1615</issue>
<page-range>20120407</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horwitz]]></surname>
<given-names><![CDATA[A. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Wakefield]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
</person-group>
<source><![CDATA[The loss of sadness: how psychiatry transformed normal sorrow into depressive disorder]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Oxford ; New York ]]></publisher-loc>
<publisher-name><![CDATA[Oxford University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kendell]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Jablensky]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distinguishing Between the Validity and Utility of Psychiatric Diagnoses]]></article-title>
<source><![CDATA[American Journal of Psychiatry]]></source>
<year>2003</year>
<volume>160</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-12</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirsch]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[The emperor&#8217;s new drugs: exploding the antidepressant myth]]></source>
<year>2010</year>
<publisher-loc><![CDATA[New York, NY ]]></publisher-loc>
<publisher-name><![CDATA[Basic Books]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[P. D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Listening to Prozac]]></source>
<year>1993</year>
<publisher-loc><![CDATA[New York, N.Y., U.S.A ]]></publisher-loc>
<publisher-name><![CDATA[Viking]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyzar]]></surname>
<given-names><![CDATA[E. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[C. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gainetdinov]]></surname>
<given-names><![CDATA[R. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[D. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Kalueff]]></surname>
<given-names><![CDATA[A. V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychedelic Drugs in Biomedicine]]></article-title>
<source><![CDATA[Trends in Pharmacological Sciences]]></source>
<year>2017</year>
<volume>38</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>992-1005</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leary]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Metzner]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Alpert]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[The psychedelic experience: a manual based on the &#8220;Tibetan book of the dead.&#8221;]]></source>
<year>2008</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Penguin]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mellor Marsá]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Aragona]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[De la categoría a la dimensión: una mirada crítica a la evolución de la nosografía psiquiátrica]]></article-title>
<source><![CDATA[Revista de la Asociación Española de Neuropsiquiatría]]></source>
<year>2009</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychedelics as Medicines: An Emerging New Paradigm]]></article-title>
<source><![CDATA[Clinical Pharmacology &amp; Therapeutics]]></source>
<year>2017</year>
<volume>101</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>209-19</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oram]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962]]></article-title>
<source><![CDATA[Journal of the History of Medicine and Allied Sciences]]></source>
<year>2014</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>221-50</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regier]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Narrow]]></surname>
<given-names><![CDATA[W. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[D. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Kraemer]]></surname>
<given-names><![CDATA[H. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuramoto]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuhl]]></surname>
<given-names><![CDATA[E. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kupfer]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DSM-5 Field Trials in the United States and Canada, Part II: Test-Retest Reliability of Selected Categorical Diagnoses]]></article-title>
<source><![CDATA[American Journal of Psychiatry]]></source>
<year>2013</year>
<volume>170</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-70</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robins]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Guze]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Establishment of Diagnostic Validity in Psychiatric Illness - Its Application to Schizophrenia]]></article-title>
<source><![CDATA[American Journal of Psychiatry]]></source>
<year>1970</year>
<volume>126</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>983-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roseman]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Leech]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Feilding]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nutt]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Carhart-Harris]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers]]></article-title>
<source><![CDATA[Frontiers in Human Neuroscience]]></source>
<year>2014</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roseman]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Nutt]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Carhart-Harris]]></surname>
<given-names><![CDATA[R. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression]]></article-title>
<source><![CDATA[Frontiers in Pharmacology]]></source>
<year>2018</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Bossis]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Guss]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Agin-Liebes]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Malone]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[B. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial]]></article-title>
<source><![CDATA[Journal of Psychopharmacology]]></source>
<year>2016</year>
<volume>30</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1165-80</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherwood]]></surname>
<given-names><![CDATA[J. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Stolaroff]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Harman]]></surname>
<given-names><![CDATA[W. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Psychedelic Experience - A New Concept in Psychotherapy]]></article-title>
<source><![CDATA[Journal of Psychedelic Drugs]]></source>
<year>1968</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>96-111</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Praag]]></surname>
<given-names><![CDATA[H. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monoaminas y depresión: una visión retrospectiva]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[López-Muñoz]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Álamo González]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Historia de la psicofarmacología]]></source>
<year>2007</year>
<volume>1</volume>
<page-range>517-44</page-range><publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zachar]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Jablensky]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Introduction: the concept of validation in psychiatry and psychology]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Zachar]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Stoyanov]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Aragona]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhablenski]]></surname>
<given-names><![CDATA[A. V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Alternative perspectives on psychiatric validation: DSM, ICD, RDoC, and beyond]]></source>
<year>2015</year>
<edition>1st</edition>
<page-range>3-24</page-range><publisher-loc><![CDATA[Oxford ]]></publisher-loc>
<publisher-name><![CDATA[Oxford University Press]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
